Literature DB >> 24744978

AMD3100 protects from UV-induced skin cancer.

Scott N Byrne1, Seri Ne Sarchio2.   

Abstract

Sunlight causes skin cancer by directly damaging DNA as well as by suppressing antitumor immune responses. A major mechanism whereby sunlight exerts immunosuppressive effects is by modulating the migration of chemokine (C-X-C motif) receptor 4 (CXCR4)-expressing dermal mast cells into and away from the skin. We have demonstrated the importance of this by showing that the systemic administration of the CXCR4 antagonist AMD3100 prevents sunlight-induced immunosuppression as well as the consequent carcinogenic response. Our results highlight the therapeutic potential of antagonizing CXCR4 signaling, especially in individuals who are at high risk of developing skin cancer.

Entities:  

Keywords:  chemokines; immunosuppression; mast cells; skin cancer; sunlight; ultraviolet radiation

Year:  2014        PMID: 24744978      PMCID: PMC3989298          DOI: 10.4161/onci.27562

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  10 in total

1.  Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.

Authors:  Devita Surjana; Gary M Halliday; Andrew J Martin; Fergal J Moloney; Diona L Damian
Journal:  J Invest Dermatol       Date:  2012-02-02       Impact factor: 8.551

Review 2.  The suppressive effects of ultraviolet radiation on immunity in the skin and internal organs: implications for autoimmunity.

Authors:  Gary M Halliday; Diona L Damian; Sabita Rana; Scott N Byrne
Journal:  J Dermatol Sci       Date:  2011-12-24       Impact factor: 4.563

3.  Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression.

Authors:  Scott N Byrne; Alberto Y Limón-Flores; Stephen E Ullrich
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

4.  Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B.

Authors:  Michele A Grimbaldeston; Susumu Nakae; Janet Kalesnikoff; Mindy Tsai; Stephen J Galli
Journal:  Nat Immunol       Date:  2007-09-02       Impact factor: 25.606

5.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

Authors:  Elda Righi; Satoshi Kashiwagi; Jianping Yuan; Michael Santosuosso; Pierre Leblanc; Rachel Ingraham; Benjamin Forbes; Beth Edelblute; Brian Collette; Deyin Xing; Magdalena Kowalski; Maria Cristina Mingari; Fabrizio Vianello; Michael Birrer; Sandra Orsulic; Glenn Dranoff; Mark C Poznansky
Journal:  Cancer Res       Date:  2011-07-08       Impact factor: 12.701

6.  Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

Authors:  Ying Ma; Rosa F Hwang; Craig D Logsdon; Stephen E Ullrich
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

7.  Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer.

Authors:  Seri N E Sarchio; Richard A Scolyer; Clare Beaugie; David McDonald; Felix Marsh-Wakefield; Gary M Halliday; Scott N Byrne
Journal:  J Invest Dermatol       Date:  2013-10-14       Impact factor: 8.551

8.  Inhibition of stromal CXCR4 impairs development of lung metastases.

Authors:  Crescenzo D'Alterio; Antonio Barbieri; Luigi Portella; Giuseppe Palma; Marianeve Polimeno; Anna Riccio; Caterina Ieranò; Renato Franco; Giosuè Scognamiglio; Jane Bryce; Antonio Luciano; Domenica Rea; Claudio Arra; Stefania Scala
Journal:  Cancer Immunol Immunother       Date:  2012-03-08       Impact factor: 6.968

Review 9.  The immunologic revolution: photoimmunology.

Authors:  Stephen E Ullrich; Scott N Byrne
Journal:  J Invest Dermatol       Date:  2011-12-15       Impact factor: 8.551

10.  Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice.

Authors:  P H Hart; M A Grimbaldeston; G J Swift; A Jaksic; F P Noonan; J J Finlay-Jones
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

  10 in total
  5 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 2.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 3.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

4.  Dermal fibroblast expression of stromal cell-derived factor-1 (SDF-1) promotes epidermal keratinocyte proliferation in normal and diseased skin.

Authors:  Chunji Quan; Moon Kyun Cho; Yuan Shao; Laurel E Mianecki; Eric Liao; Daniel Perry; Taihao Quan
Journal:  Protein Cell       Date:  2015-08-22       Impact factor: 14.870

5.  Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells.

Authors:  N Puebla-Osorio; E Damiani; L Bover; S E Ullrich
Journal:  Cell Death Dis       Date:  2015-05-07       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.